The Prevalence of Potential Drug-Drug Interactions in Patients with Heart Failure at Hospital Discharge (original) (raw)

• Masoudi FA, Krumholz HM. Polypharmacy and comorbidity in heart failure. BMJ 2003; 327(7414): 513–4
  Article PubMed Google Scholar
• Ledwidge M, Travers B, Ryder M, et al. Specialist care of heart failure improves appropriate pharmacotherapy at the expense of greater polypharmacy and drug-interactions. Eur J Heart Fail 2004; 6(2): 235–43
  Article PubMed CAS Google Scholar
• Martinez-Selles M, Garcia Robles JA, Munoz R, et al. Pharmacological treatment in patients with heart failure: patients knowledge and occurrence of polypharmacy, alternative medicine and immunizations. Eur J Heart Fail 2004; 6(2): 219–26
  Article PubMed Google Scholar
• Seymour RM, Routledge PA. Important drug-drug interactions in the elderly. Drugs Aging 1998; 12(6): 485–94
  Article PubMed CAS Google Scholar
• Köhler GI, Bode-Boger SM, Busse R, et al. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 2000; 38(11): 504–13
  PubMed Google Scholar
• Ratz Bravo A, Tchambaz L, Krahenbuhl-Melcher A, et al. The prevalence of potentially critical drug-drug interactions in ambulatory dyslipidemic patients treated with statins. Drug Saf 2005; 28(3): 263–75
  Article PubMed Google Scholar
• Bjerrum L, Andersen M, Petersen G, et al. Exposure to potential drug interactions in primary health care. Scand J Prim Health Care 2003; 21(3): 153–8
  Article PubMed Google Scholar
• Egger SS, Drewe J, Schlienger RG. Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol 2003; 58(11): 773–8
  PubMed Google Scholar
• Krum H, Gilbert RE. Demographics and concomitant disorders in heart failure. Lancet 2003; 362(9378): 147–58
  Article PubMed Google Scholar
• Rosholm JU, Bjerrum L, Hallas J, et al. Polypharmacy and the risk of drug-drug interactions among Danish elderly: a prescription database study. Dan Med Bull 1998; 45(2): 210–3
  PubMed CAS Google Scholar
• Bergk V, Gasse C, Rothenbacher D, et al. Drug interactions in primary care: impact of a new algorithm on risk determination. Clin Pharmacol Ther 2004; 76(1): 85–96
  Article PubMed CAS Google Scholar
• Bergendal L, Friberg A, Schaffrath A. Potential drug-drug interactions in 5,125 mostly elderly out-patients in Gothenburg, Sweden. Pharm World Sci 1995; 17(5): 152–7
  Article PubMed CAS Google Scholar
• Björkman IK, Fastbom J, Schmidt IK, et al. Drug-drug interactions in the elderly. Ann Pharmacother 2002; 36(11): 1675–81
  Article PubMed Google Scholar
• Jankel CA, Fitterman LK. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf 1993; 9(1): 51–9
  Article PubMed CAS Google Scholar
• Di Castri A, Jacquot JM, Hemmi P, et al. Intéractions médicamenteuses: etudes de 409 ordonnances établies à l’issue d’une hospitalisation gériatrique. Therapie 1995; 50(3): 259–64
  PubMed Google Scholar
• Dettli L. Drug dosage in patients with renal disease. Clin Pharmacol Ther 1974; 16(1): 274–80
  PubMed CAS Google Scholar
• Klasco RK, Moore LE. Drug-Reax® System. Greenwood Village (CO): MICROMEDEX, 2004
  Google Scholar
• Gaddis GM, Holt TR, Woods M. Drug interactions in at-risk emergency department patients. Acad Emerg Med 2002; 9(11): 1162–7
  Article PubMed Google Scholar
• Langdorf MI, Fox JC, Marwah RS, et al. Physician versus computer knowledge of potential drug interactions in the emergency department. Acad Emerg Med 2000; 7(11): 1321–9
  Article PubMed CAS Google Scholar
• Meredith PA. Is postural hypotension a real problem with antihypertensive medication? Cardiology 2001; 96Suppl. 1: 19–24
  Article PubMed CAS Google Scholar
• Mignat C, Unger T. ACE inhibitors: drug interactions of clinical significance. Drug Saf 1995; 12(5): 334–47
  Article PubMed CAS Google Scholar
• Tan LB, Williams SG, Goldspink DF. From CONSENSUS to CHARM: how do ACEI and ARB produce clinical benefits in CHF? Int J Cardiol 2004; 94(2-3): 137–41
  Article PubMed CAS Google Scholar
• Klein L, O’Connor CM, Gattis WA, et al. Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. Am J Cardiol 2003; 91(9A): 18F–40F
  Article PubMed CAS Google Scholar
• Bouvy ML, Heerdink ER, Leufkens HG, et al. Patterns of pharmacotherapy in patients hospitalised for congestive heart failure. Eur J Heart Fail 2003; 5(2): 195–200
  Article PubMed CAS Google Scholar
• Ageno W, Turpie AG. Low molecular weight heparins in the treatment of unstable angina. Minerva Cardioangiol 2002; 50(6): 643–51
  PubMed CAS Google Scholar
• Shullo MA, Rose ML, Vivas C, et al. Hemorrhagic complications of enoxaparin and aspirin in patients with kidney transplants. Pharmacotherapy 2002; 22(2): 184–7
  Article PubMed CAS Google Scholar
• Farooq V, Hegarty J, Chandrasekar T, et al. Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. Am J Kidney Dis 2004; 43(3): 531–7
  Article PubMed Google Scholar
• Haustein KO. Pharmacokinetic and pharmacodynamic properties of oral anticoagulants, especially phenprocoumon. Semin Thromb Hemost 1999; 25(1): 5–11
  Article PubMed CAS Google Scholar
• Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med 2000; 109(4): 307–14
  Article PubMed CAS Google Scholar
• McAlister FA, Ezekowitz J, Tonelli M, et al. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109(8): 1004–9
  Article PubMed Google Scholar
• Schepkens H, Vanholder R, Billiouw JM, et al. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001; 110(6): 438–41
  Article PubMed CAS Google Scholar
• Svensson M, Gustafsson F, Galatius S, et al. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail 2004; 10(4): 297–303
  Article PubMed CAS Google Scholar
• Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors: how much should we worry? Arch Intern Med 1998; 158(1): 26–32
  Article PubMed CAS Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341(10): 709–17
  Article PubMed CAS Google Scholar
• Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351(6): 543–51
  Article PubMed CAS Google Scholar
• Morimoto T, Gandhi TK, Fiskio JM, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract 2004; 10(4): 499–509
  Article PubMed Google Scholar
• Leor J, Levartowsky D, Sharon C, et al. Amiodarone and betaadrenergic blockers: an interaction with metoprolol but not with atenolol. Am Heart J 1988; 116(1 Pt 1): 206–7
  Article PubMed CAS Google Scholar
• Yamreudeewong W, DeBisschop M, Martin L, et al. Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf 2003; 26(6): 421–38
  Article PubMed CAS Google Scholar
• Boutitie F, Boissel JP, Connolly SJ, et al. Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. Circulation 1999; 99(17): 2268–75
  Article PubMed CAS Google Scholar
• Krum H, Shusterman N, MacMahon S, et al. Efficacy and safety of carvedilol in patients with chronic heart failure receiving concomitant amiodarone therapy. Australia/New Zealand Heart Failure Research Collaborative Group. J Card Fail 1998; 4(4): 281–8
  Article PubMed CAS Google Scholar
• Herrlinger C, Klotz U. Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol 2001; 15(6): 897–918
  Article PubMed CAS Google Scholar
• Juurlink DN, Mamdani MM, Kopp A, et al. A population-based assessment of the potential interaction between serotonin-specific reuptake inhibitors and digoxin. Br J Clin Pharmacol 2005; 59(1): 102–7
  Article PubMed CAS Google Scholar
• Chen YF, Avery AJ, Neil KE, et al. Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice. Drug Saf 2005; 28(1): 67–80
  Article PubMed Google Scholar
• Egger T, Dormann H, Ahne G, et al. Identification of adverse drug reactions in geriatric inpatients using a computerised drug database. Drugs Aging 2003; 20(10): 769–76
  Article PubMed CAS Google Scholar